Mirna Therapeutics (NASDAQ:MIRN) target price lowered to $2.00, reported today by Citigroup
- Updated: September 22, 2016
Just yesterday Mirna Therapeutics (NASDAQ:MIRN) traded 1.00% higher at $2.02. Mirna Therapeutics’s 50-day moving average is $3.11 and its 200-day moving average is $4.10. The last stock price is down -50.73% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 28,110 shares of MIRN traded hands, up from an average trading volume of 26,870
Mirna Therapeutics (NASDAQ:MIRN) had its target price lowered to $2.00 by Citigroup in a report released 9/22/2016. The new target price indicates a possible downside of -0.01% based on the company's previous stock price.
Recent Performance Chart
Mirna Therapeutics has 52 week low of $1.82 and a 52 week high of $11.01 and has a market capitalization of $0.
In addition to Citigroup reporting its stock price target, a total of 4 brokerages have issued a research note on the company. The average stock price target is $11.00 with 3 brokerages rating the stock a strong buy, 1 brokerage rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Mirna Therapeutics (NASDAQ:MIRN)
Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company's RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.